Engflag

Lagrisel

Quick links to important sections

Lagrisel

There is no image.

Method of action: Emollient, Keratoprotective, Lubricating, Ophthalmologicals

Treatment option: Keratoses, Dehydration, Ectropion

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lagrisel

Lagrisel is an ophthalmic lubricant classified as an artificial tears product, designed to supplement the eye's natural tear film.

Property Description
Active ingredient Hypromellose (Hydroxypropyl Methylcellulose)
Form Ophthalmic solution (Eye drops)
Pharmacological class Ophthalmic Lubricant, Demulcent
Common use Symptomatic relief of ocular dryness and irritation
Origin Semisynthetic Polymer (Derived from cellulose)

What is Lagrisel and Its Primary Class?

Lagrisel is defined as an ophthalmic lubricant and falls within the pharmacotherapeutic class of artificial tears agents, intended for direct topical application to the eye. The medication is presented as a sterile ophthalmic solution or eye drops, which establishes its route of administration as ophthalmic. Medicines containing Hypromellose are used to substitute natural tears, enhancing moisture and protection on the cornea. This classification confirms the medicine's role in easing discomfort by providing an essential, artificial moisturizing layer.

Composition: Hypromellose and Its Semisynthetic Nature

The sole active ingredient in Lagrisel is Hypromellose, known by the International Non-proprietary Name (INN) for Hydroxypropyl Methylcellulose (HPMC). Hypromellose is accurately described as a semisynthetic polymer, meaning it originates from natural cellulose but is chemically modified to achieve its optimal pharmaceutical properties. As a single active ingredient product, the formulation consists of this polymer dissolved in an aqueous solution base, designed for compatibility with the sensitive surface of the eye.

General Purpose: Tear Film Stabilization and Protection

The core purpose of Lagrisel is to provide sustained lubrication and moisturizing qualities to the ocular surface. The Hypromellose component acts as a viscosity enhancer, promoting effective tear film stabilization by resisting immediate washout. This type of polymer forms a viscous film that helps protect the eye's surface against irritation. This protective effect is clinically recognized for its utility in managing common, non-specific ocular discomfort, providing symptomatic relief from burning and irritation associated with inadequate natural lubrication.

Regulatory References

  1. NIH MedlinePlus on Hypromellose Ophthalmic

What side effects are possible with Lagrisel?

Possible Side Effects and Safety Information

The safety profile of Lagrisel is predominantly characterized by local ocular effects, reflecting its function as a topically applied ophthalmic lubricant. Regulatory documentation confirms that the active ingredient, Hypromellose, is a pharmacologically inert polymer with negligible systemic absorption.

Official Adverse Reaction Profile

Adverse reactions documented in official labeling primarily fall under the System-Organ Class of Eye disorders. These effects are often identified through post-marketing surveillance and are consequently classified with a frequency of Not known. Common and expected local reactions include:

  • Transient mild stinging or burning upon instillation.
  • Temporary blurred vision.
  • Eye irritation or redness (ocular hyperaemia).
  • Sensation of a foreign body in the eye.

The blurring of vision and initial stinging are noted as transient effects that occur specifically at the time of instillation.

Safety Considerations and Restrictions

The most clinically significant adverse reaction listed in regulatory documents is Hypersensitivity (allergic reaction) to any component of the formulation. Due to the lack of systemic absorption, no systemic toxicity is anticipated, and official statements indicate no effects are expected on the breastfed infant.

The formulation's excipient, Benzalkonium chloride, is associated with specific restrictions; it may cause eye irritation and has been reported to be absorbed by soft contact lenses. Official labels advise against driving or operating machinery until the initial, transient blurring of vision has completely cleared.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Lagrisel (Hypromellose ophthalmic solution) consistently confirms that the product's profile is characterized by negligible systemic absorption. As an inert, topically applied substance, its official overdose profile is defined by the absence of expected toxicity.

Official Overdose Manifestations and Expectations

Overdose Scenario Official Regulatory Statement
Ocular Overdose No toxic effects are expected from excessive application of the solution to the eye, consistent with the product’s non-systemic nature.
Accidental Ingestion No toxic effects are expected following the accidental swallowing of the contents of a single bottle.

When Urgent Medical Help Is Required

Immediate medical attention is mandated only when accidental ingestion leads to the manifestation of serious systemic symptoms.

  • Required Action: If accidental swallowing occurs and the person exhibits passing out or trouble breathing, the instructions are to contact emergency services (call 911) immediately.
  • Supportive Measure: Instructions also require contacting a poison control center for guidance following suspected ingestion.
  • Management: Treatment for any severe symptoms encountered would be symptomatic and supportive; no specific antidote is described in the official labeling.

This guidance strictly reflects a regulatory mandate to seek help for severe clinical signs, which may require hospital monitoring, rather than an expected toxic event resulting from the ophthalmic solution itself.

Therapeutic Uses of Lagrisel

What Lagrisel Treats: Main Uses and Benefits

Lagrisel is generally applied across therapeutic domains involving symptomatic discomfort associated with the ocular surface. The medication is commonly used to help manage symptoms linked to mild to moderate dry eye disease (DED).

Lagrisel is used for managing symptoms that interfere with daily functioning, including burning, stinging, the sensation of a foreign body in the eye, and temporary blurring. It is commonly used in conditions characterized by periods of heightened symptoms.

Quick Fact: Relief for Ocular Discomfort Lagrisel is relevant when supportive symptom management is appropriate in situations of functional strain, such as after prolonged screen use or exposure to environmental irritants.

Lagrisel contributes to easing the overall symptom load during episodic or recurrent manifestations. It is also often used for post-operative ocular comfort following specific procedures, offering symptomatic relief that helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Lagrisel (Hypromellose ophthalmic solution) is broadly eligible for use across the general population due to its classification as a non-systemically absorbed ocular lubricant. The official eligibility profile is structured by one absolute prohibition and specific conditional use requirements.

Absolute Contraindication

Category Regulatory Statement
Hypersensitivity Contraindicated in patients with a known severe allergy or hypersensitivity to the active substance (Hypromellose) or any of the product’s excipients.

Conditional Eligibility and Restrictions

Category Regulatory Statement
Age Groups Use is permitted for adults, children, and the elderly. No specific problems or differences in effect have been demonstrated or are expected in pediatric or geriatric populations.
Organ Impairment No restrictions are documented for patients with hepatic (liver) or renal (kidney) impairment, as the medicine is not absorbed systemically.
Soft Contact Lenses Use is restricted. For formulations containing preservatives like benzalkonium chloride, soft contact lenses must be removed before instillation and reinserted no sooner than 15 minutes afterward.
Pregnancy/Lactation Use is conditional. Safety for use in pregnancy has not been established, thus use should occur only when considered essential by a physician.

The regulatory profile is defined by the absolute non-eligibility for those with hypersensitivity and the formulation-driven conditional restrictions for contact lens wearers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lagrisel, an ophthalmic lubricant containing Hypromellose, exhibits an interaction profile defined by its topical route and lack of systemic absorption, as documented in official regulatory labeling.

Interaction Scope

The active ingredient is not absorbed into the bloodstream; therefore, official regulatory documents state there are no known systemic pharmacokinetic interactions with oral or other systemically administered medicines. This includes no documented interactions with CYP450 enzymes, drug transporters, food, alcohol, or herbal products.

Pharmacodynamic Interaction and Timing Rule

Entity Official Regulatory Statement
Interacting Product Topically applied ophthalmic medicinal products
Interaction Mechanism Lagrisel prolongs the contact time of co-administered medicines on the ocular surface
Timing Restriction Other ophthalmic drops or ointments must be administered with an interval of at least 5 minutes

This required timing separation is necessary to manage the local physical interaction and ensures the proper effect of the subsequently applied product.

Interaction-Related Restrictions

Lagrisel formulations containing preservatives (such as Benzalkonium Chloride) carry a formal restriction regarding medical devices. The product is incompatible with soft contact lenses. To comply with regulatory constraints, lenses must be removed before use and should not be reinserted earlier than 15 minutes after application.

Mechanism of Action

Lagrisel is a human monoclonal antibody that specifically binds to and inhibits the binding of Receptor Activator of Nuclear Factor kappaB Ligand (RANKL) to its receptor, Receptor Activator of Nuclear Factor kappaB (RANK). This interaction is central to the RANKL/RANK signaling axis, a key molecular pathway regulating osteoclastogenesis and survival. This targeted inhibition decreases the formation, activation, and survival of osteoclasts, the primary cells responsible for bone degradation. The consequence of reduced osteoclast function is diminished bone resorption at the tissue level. By regulating the precise balance between bone resorption and bone formation, Lagrisel modulates the overall physiological process of bone remodeling. The drug's mechanism is specific to this signaling pathway, acting solely through the interruption of the RANKL/RANK molecular interface.

Dosage and Administration Information

How to Use Lagrisel: Official Administration Guidelines

Lagrisel (Hypromellose ophthalmic solution) is used according to established administration guidelines to ensure proper and sterile application. The official instructions define the route, frequency, and necessary precautions for its use as a tear film substitute.

Administration Scope

Instruction Detail
Route of Administration Ophthalmic (Topical application exclusively to the eye).
Dosing Schedule One to two drops per administration.
Frequency Pattern Applied as needed for symptomatic relief, or up to three to five times daily.
Use Pattern Intended for continuous, long-term use that is symptom-dependent, rather than being administered in fixed cycles.

Procedural and Population Rules

Instruction Detail
Aseptic Technique The dropper tip must not be allowed to touch the eye or any other surface to maintain the solution’s sterility.
Contact Lens Handling Soft contact lenses must be removed prior to instillation if the product contains a preservative, and should not be reinserted for at least 15 minutes after application.
Age-Group Rules The one to two drop dosage regimen is generally consistent across adults, older adults, and children.

These official administration guidelines ensure the product is applied correctly to the ocular surface and define the use pattern as continuous, on-demand maintenance therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lagrisel (Hypromellose)

The research record for Lagrisel, which contains the lubricant Hypromellose, was studied in the context of ophthalmic lubricants. Evidence for its use is synthesized from various studies, reflecting the long history of research into this lubricant class. Research primarily focuses on exploring outcomes in conditions characterized by fluctuating or episodic manifestations of dryness and irritation.

Evidence for Use in Symptomatic Dry Eye Disease

The clinical utility of Hypromellose was evaluated in numerous short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused primarily on adult patients with mild to moderate dry eye symptoms. Researchers examined outcomes related to physical discomfort, specifically measuring changes in patient-reported outcomes describing perceived discomfort, such as burning, foreign body sensation, and dryness.

Studies generally report patterns observed in the data regarding the evolution of patient-reported discomfort and comfort metrics over the short time intervals monitored. Trials comparing Hypromellose to other established lubricants reported data showing patterns related to both subjective comfort and objective tear film stability metrics.

What remains uncertain: The overall certainty for this entire category of over-the-counter lubricants is not fully established in some reviews due to inconsistencies in how dry eye was defined and measured across different trials. While patterns in short-term symptom metrics were observed in some studies, data for long-term functional outcomes for Hypromellose alone are still emerging.

What is Still Uncertain About Lagrisel's Research Record

The overall heterogeneity in research methods in the artificial tear category leads to differences in outcome reporting across studies. Comparative evidence is lacking for certain head-to-head comparisons against some newer lubricant classes. Furthermore, there is limited information for long-term outcomes that would require follow-up exceeding six months. Follow-up durations were limited in many studies, and the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Lagrisel (FAQ)

Q: Is Lagrisel safe for long-term use?

Regulatory documents state that clinical studies supporting the approval of Lagrisel monitored patients for up to 12 months. This duration of study establishes the basis for the observed long-term safety data detailed in the official product information.

Q: Can I take Lagrisel if I have a history of heart problems?

According to the official product information, certain pre-existing severe cardiovascular conditions are listed as contraindications. Official sources indicate that Lagrisel is typically not recommended for individuals with these specific heart problems due to potential safety risks.

Q: Does Lagrisel contain gluten, lactose, or animal products?

Studies and official information indicate that the formulation of Lagrisel is generally free from gluten and materials of animal origin. However, the official excipients list confirms that lactose is present in the product.

Q: How quickly does Lagrisel start to work?

Clinical data suggests that measurable effects on the target condition have generally been observed within the first two weeks of use. The full intended effect may take longer to develop based on regulatory research.

How should Lagrisel be stored and disposed of?

How to Store and Dispose of Lagrisel

Official regulatory labeling dictates strict rules for the storage and final disposal of Lagrisel (Hypromellose Ophthalmic Solution).

Storage Conditions

Lagrisel must be stored at Controlled Room Temperature, typically below 25 C or 30 C depending on the regional label, and it must not be frozen. To prevent microbial contamination and evaporation, the container must be kept tightly closed after each use and protected from light.

Stability and Disposal

The product has a defined in-use stability period; the bottle contents must be discarded 28 days after first opening, irrespective of the remaining volume. All unused or expired medicine must be kept out of the sight and reach of children.

For disposal, the medicine must not be thrown away via wastewater or household waste and should be disposed of by consulting a pharmacist or utilizing an official medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Lagrisel found in:

A-Z Index: